QPPV.COM KNOWLEDGE ASSESSMENT

EU Marketing Authorisation Procedures: Professional Knowledge Assessment

Test your understanding of the concepts covered by Centralised, National, Mutual Recognition and Decentralised Procedures Explained.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which sequence best represents the centralised procedure for a human medicine?

National competent authority assessment, CMDh agreement, national authorisations EMA submission, CHMP scientific opinion, European Commission legally binding decision RMS assessment, CMS review, national decisions without EU involvement PRAC opinion, national authority decision, European Commission endorsement

Question 2 of 10 Why should a safety concern not automatically be labelled an Article 29(4) matter?

Article 29 applies only to centrally authorised medicines The phrase potential serious risk to public health is a specific legal and procedural threshold, not a synonym for any clinically important concern Article 29 is used only for product translations Safety concerns can never lead to disagreement procedures

Question 3 of 10 Which combination correctly pairs a route with its authorisation outcome?

Centralised procedure — multiple national marketing authorisations National procedure — automatic authorisation throughout the EU MRP — national authorisations recognising an existing national authorisation and assessment DCP — one European Commission decision for all participating countries

Question 4 of 10 A regulatory professional sees RMS, CMS, CMDh and a procedure number in a document. What is the most reasonable first-pass interpretation?

The document most likely concerns an MRP or DCP product The document must concern a centrally authorised product The document is necessarily a national-only procedure with no European coordination The document is necessarily an inspection report rather than an authorisation document

Question 5 of 10 Which decision framework best captures the initial route-selection logic for a product intended for several Member States?

First determine whether centralisation is mandatory; if not, determine whether an EU national authorisation already exists; if neither applies, consider DCP eligibility Always begin with DCP, then convert to MRP if an authorisation is granted Select the route solely on the basis of the number of Member States Use MRP whenever the product is not centrally authorised, regardless of whether an existing national authorisation exists

Question 6 of 10 What is the essential difference between MRP and DCP?

MRP involves EMA, whereas DCP never involves national authorities MRP begins with an existing national authorisation, whereas DCP begins without an existing EU national authorisation MRP produces a Union authorisation, whereas DCP produces a scientific opinion MRP is limited to safety issues, whereas DCP is limited to efficacy issues

Question 7 of 10 A company seeks authorisation only in one Member State for a product that is not subject to mandatory centralisation. Which route is generally most directly aligned with that objective?

National procedure Mutual-recognition procedure Decentralised procedure Article 29 procedure

Question 8 of 10 Which statement best describes the role of CMSs in MRP and DCP?

They merely record the RMS conclusion without scientific review They independently repeat the entire procedure without reference to the RMS They participate in reviewing the assessment, raising concerns and reaching a coordinated outcome They act as branches of EMA for national implementation

Question 9 of 10 What is the most important distinction between the four EU marketing-authorisation routes described in the article?

They apply different scientific standards for evaluating benefit-risk They determine the procedural and legal architecture through which authorisation is obtained and maintained They determine whether pharmacovigilance obligations apply after authorisation They rank Member State authorities according to scientific capability

Question 10 of 10 Which body is principally associated with coordinating questions concerning human medicines authorised in two or more Member States through MRP or DCP?

CHMP CMDh European Commission The RMS alone

EU Marketing Authorisation Procedures: Professional Knowledge Assessment

Cookie Settings